Advertisement
Singapore markets open in 4 hours 4 minutes

  • Straits Times Index

    3,084.08
    -6.23 (-0.20%)
     

  • S&P 500

    4,570.72
    -23.91 (-0.52%)
     

  • Dow

    36,224.74
    -20.76 (-0.06%)
     

  • Nasdaq

    14,186.49
    -118.54 (-0.83%)
     

  • Bitcoin USD

    41,764.36
    +2,175.01 (+5.49%)
     

  • CMC Crypto 200

    858.99
    +0.28 (+0.03%)
     

  • FTSE 100

    7,512.96
    -16.39 (-0.22%)
     

  • Gold

    2,046.30
    -43.40 (-2.08%)
     

  • Crude Oil

    73.26
    -0.81 (-1.09%)
     

  • 10-Yr Bond

    4.2880
    +0.0620 (+1.47%)
     

  • Nikkei

    33,231.27
    -200.24 (-0.60%)
     

  • Hang Seng

    16,646.05
    -184.25 (-1.09%)
     

  • FTSE Bursa Malaysia

    1,451.02
    -5.36 (-0.37%)
     

  • Jakarta Composite Index

    7,093.60
    +33.69 (+0.48%)
     

  • PSE Index

    6,284.37
    +39.19 (+0.63%)
     

Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference

Business Wire
·1-min read

CAMBRIDGE, Mass. & MONTREAL, September 06, 2023--(BUSINESS WIRE)--Repare Therapeutics Inc. ("Repare" or the "Company") (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that members of its senior management team will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Wednesday, September 13, 2023, at 11:30 a.m. Eastern Time in New York, NY.

A live webcast of the fireside chat can be accessed in the Investor section of the Company’s website at https://ir.reparerx.com/news-and-events/events. A replay of the webcast will be archived on the Company’s website for 90 days.

About Repare Therapeutics, Inc.

Repare Therapeutics is a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx® platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The Company’s pipeline includes lunresertib (also known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical development; camonsertib (also known as RP-3500 or RG6526), a potential leading ATR inhibitor currently in Phase 1/2 clinical development and partnered with Roche; RP-3467, a preclinical Polθ inhibitor program; as well as several additional, undisclosed preclinical programs, including RP-1664. For more information, please visit reparerx.com.

SNIPRx® is a registered trademark of Repare Therapeutics Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230906864610/en/

Contacts

Repare Contact:

Steve Forte
Executive Vice-President and Chief Financial Officer
Repare Therapeutics Inc.
investor@reparerx.com

Investors:

Matthew DeYoung
Argot Partners
repare@argotpartners.com

Media:

David Rosen
Argot Partners
david.rosen@argotpartners.com
212-600-1902